• Home
  • Search Results
  • PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome.

PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome.

American journal of human genetics (2013-04-09)
Peter M Krawitz, Yoshiko Murakami, Angelika Rieß, Marja Hietala, Ulrike Krüger, Na Zhu, Taroh Kinoshita, Stefan Mundlos, Jochen Hecht, Peter N Robinson, Denise Horn
ABSTRACT

Recently, mutations in genes involved in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor have been identified in a new subclass of congenital disorders of glycosylation (CDGs) with a distinct spectrum of clinical features. To date, mutations have been identified in six genes (PIGA, PIGL, PIGM, PIGN, PIGO, and PIGV) encoding proteins in the GPI-anchor-synthesis pathway in individuals with severe neurological features, including seizures, muscular hypotonia, and intellectual disability. We developed a diagnostic gene panel for targeting all known genes encoding proteins in the GPI-anchor-synthesis pathway to screen individuals matching these features, and we detected three missense mutations in PGAP2, c.46C>T, c.380T>C, and c.479C>T, in two unrelated individuals with hyperphosphatasia with mental retardation syndrome (HPMRS). The mutations cosegregated in the investigated families. PGAP2 is involved in fatty-acid GPI-anchor remodeling, which occurs in the Golgi apparatus and is required for stable association between GPI-anchored proteins and the cell-surface membrane rafts. Transfection of the altered protein constructs, p.Arg16Trp (NP_001243169.1), p.Leu127Ser, and p.Thr160Ile, into PGAP2-null cells showed only partial restoration of GPI-anchored marker proteins, CD55 and CD59, on the cell surface. In this work, we show that an impairment of GPI-anchor remodeling also causes HPMRS and conclude that targeted sequencing of the genes encoding proteins in the GPI-anchor-synthesis pathway is an effective diagnostic approach for this subclass of CDGs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phosphatase, Alkaline bovine, recombinant, expressed in Pichia pastoris, ≥4000 units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥4,000 DEA units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, ≥2,000 DEA units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous solution, ≥2,000 DEA units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from porcine kidney, lyophilized powder, ≥100 DEA units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, lyophilized powder, ≥10 DEA units/mg solid
Sigma-Aldrich
Phosphatase, Alkaline from calf intestine, buffered aqueous glycerol solution
Sigma-Aldrich
Phosphatase, Alkaline from bovine kidney, lyophilized powder, ≥5 units/mg protein (Activity determined in diethanolamine buffer, pH 9.8)
Sigma-Aldrich
Phosphatase, Alkaline from Escherichia coli, lyophilized powder, 30-60 units/mg protein (in glycine buffer)
Sigma-Aldrich
Phosphatase, Alkaline from Escherichia coli, ammonium sulfate suspension, 30-90 units/mg protein (modified Warburg-Christian, in glycine buffer)
Sigma-Aldrich
Phosphatase, Alkaline from Escherichia coli, buffered aqueous glycerol solution, 20-50 units/mg protein (in glycine buffer)
Sigma-Aldrich
Phosphatase, Alkaline shrimp, ≥1,000 DEA units/mL, buffered aqueous glycerol solution, recombinant, expressed in proprietary host
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥5,500 DEA units/mg protein
Sigma-Aldrich
Phosphatase, Alkaline from bovine intestinal mucosa, BioUltra, buffered aqueous glycerol solution, ≥6,000 DEA units/mg protein